Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024 07:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference

aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
May 14, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
May 06, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to present at upcoming investor conferences.
May 02, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma announces first quarter 2024 results and provides corporate update
April 01, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma to Participate in April Investor Conferences
March 14, 2024 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
February 28, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
February 21, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants

Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
January 29, 2024 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity

aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right